Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Luo, L.-Y.
Right arrow Articles by Diamandis, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luo, L.-Y.
Right arrow Articles by Diamandis, E. P.
[Cancer Research 63, 807-811, February 15, 2003]
© 2003 American Association for Cancer Research

Clinical Investigations

The Serum Concentration of Human Kallikrein 10 Represents a Novel Biomarker for Ovarian Cancer Diagnosis and Prognosis1

Liu-Ying Luo, Dionyssios Katsaros, Andreas Scorilas, Stefano Fracchioli, Roberto Bellino, Marleen van Gramberen, Henk de Bruijn, Alfthan Henrik, Ulf-Hakan Stenman, Marco Massobrio, Ate G. J. van der Zee, Ignace Vergote and Eleftherios P. Diamandis2

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5 Canada [L-Y. L., E. P. D.]; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, M5G 1L5 Canada [L-Y. L., E. P. D.]; Department of Gynecology, Gynecologic Oncology Unit, University of Turin, Turin, Italy [D. K., S. F., R. B., M. M.]; National Center for Scientific Research "Demokritos," IPC, Athens 15310, Greece [A. S.]; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Leuven, Belgium [M. v. G., I. V.]; Department of Obstetrics and Gynecology, University Hospital Groningen, Groningen, the Netherlands [H. d. B., A. G. J. v. d. Z.]; and Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland [A. H., U-H. S.]

Human kallikrein 10 (hK10) is a secreted serine protease that is highly expressed in ovarian tissue.We hypothesized that hK10 might represent a novel serological marker for ovarian cancer. We quantified by immunoassay, hK10 in sera from 97 normal women (controls), 141 patients with benign gynecologic diseases, and 146 patients with ovarian cancer. We then examined the diagnostic and prognostic value of this measurement in ovarian cancer. We found that normal serum hK10 ranged from 50 to 1040 ng/liter (mean = 439 ng/liter). hK10 concentration is significantly elevated in serum of presurgical ovarian cancer patients (range: 106–11,746 ng/liter; mean = 1067 ng/liter) but not in serum of patients with benign gynecologic diseases (range: 120–1200 ng/liter; mean = 447 ng/liter). When a cutoff of 700 ng/liter was selected (diagnostic specificity = 90%), the diagnostic sensitivity for ovarian cancer is 54%. About 35% of CA125-negative ovarian cancer patients (CA125 < 23 kU/liter) were hK10 positive at 90% specificity. In patients with stage I/II ovarian cancer, use of these two markers in combination results in a 21% increase in sensitivity, at 90% specificity, compared with CA125 alone. High serum hK10 was strongly associated with serous epithelial type, late-stage, advanced grade, large residual tumor (>1 cm), suboptimal debulking, and no response to chemotherapy (all Ps < 0.001). In univariate Cox survival analysis, high serum hK10 is associated with increased risk for relapse and death (hazard ratio = 2.59 and 3.15, respectively, P <= 0.003). This prognostic value remains significant for overall survival in the multivariate analysis. Kaplan-Meier survival curves demonstrated similar findings. Serum hK10 represents a novel biomarker for ovarian cancer. We conclude that preoperative serum hK10 concentration is a strong and independent unfavorable prognostic marker for ovarian cancer.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
Y. Zheng, D. Katsaros, S. J.C. Shan, I. R. de la Longrais, M. Porpiglia, A. Scorilas, N. W. Kim, R. L. Wolfert, I. Simon, L. Li, et al.
A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy
Clin. Cancer Res., December 1, 2007; 13(23): 6984 - 6992.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
N. D. Kirkpatrick, M. A. Brewer, and U. Utzinger
Endogenous Optical Biomarkers of Ovarian Cancer Evaluated with Multiphoton Microscopy
Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2048 - 2057.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. W. McIntosh, Y. Liu, C. Drescher, N. Urban, and E. P. Diamandis
Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma
Clin. Cancer Res., August 1, 2007; 13(15): 4422 - 4428.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Dorn, M. Schmitt, R. Kates, B. Schmalfeldt, M. Kiechle, A. Scorilas, E. P. Diamandis, and N. Harbeck
Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients
Clin. Cancer Res., March 15, 2007; 13(6): 1742 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Meinhold-Heerlein, D. Bauerschlag, Y. Zhou, L. M. Sapinoso, K. Ching, H. Frierson Jr., K. Brautigam, J. Sehouli, E. Stickeler, D. Konsgen, et al.
An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 458 - 466.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. H. Slagter, L. J.G. Gooren, W. de Ronde, A. Soosaipillai, A. Scorilas, E. J. Giltay, M. Paliouras, and E. P. Diamandis
Serum and Urine Tissue Kallikrein Concentrations in Male-to-Female Transsexuals Treated with Antiandrogens and Estrogens
Clin. Chem., July 1, 2006; 52(7): 1356 - 1365.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Borgono, T. Kishi, A. Scorilas, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt, and E. P. Diamandis
Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer
Clin. Cancer Res., March 1, 2006; 12(5): 1487 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Simon, S. Zhuo, L. Corral, E. P. Diamandis, M. J. Sarno, R. L. Wolfert, and N. W. Kim
B7-H4 Is a Novel Membrane-Bound Protein and a Candidate Serum and Tissue Biomarker for Ovarian Cancer
Cancer Res., February 1, 2006; 66(3): 1570 - 1575.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Nagahara, K. Mimori, T. Utsunomiya, G. F. Barnard, M. Ohira, K. Hirakawa, and M. Mori
Clinicopathologic and Biological Significance of Kallikrein 6 Overexpression in Human Gastric Cancer
Clin. Cancer Res., October 1, 2005; 11(19): 6800 - 6806.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. E. Graves, E. V. Ariztia, J. R. Navari, H. J. Matzel, M. S. Stack, and D. A. Fishman
Proinvasive Properties of Ovarian Cancer Ascites-Derived Membrane Vesicles
Cancer Res., October 1, 2004; 64(19): 7045 - 7049.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Dupont, M. K. Tanwar, H. T. Thaler, M. Fleisher, N. Kauff, M. L. Hensley, P. Sabbatini, S. Anderson, C. Aghajanian, E. C. Holland, et al.
Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40
J. Clin. Oncol., August 15, 2004; 22(16): 3330 - 3339.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
C. A. Borgono, I. P. Michael, and E. P. Diamandis
Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer
Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. Kishi, A. Soosaipillai, L. Grass, S. P. Little, E. M. Johnstone, and E. P. Diamandis
Development of an Immunofluorometric Assay and Quantification of Human Kallikrein 7 in Tissue Extracts and Biological Fluids
Clin. Chem., April 1, 2004; 50(4): 709 - 716.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Scorilas, C. A. Borgono, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt, and E. P. Diamandis
Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker
J. Clin. Oncol., February 15, 2004; 22(4): 678 - 685.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. A. Iacobuzio-Donahue, R. Ashfaq, A. Maitra, N. V. Adsay, G. L. Shen-Ong, K. Berg, M. A. Hollingsworth, J. L. Cameron, C. J. Yeo, S. E. Kern, et al.
Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas: A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies
Cancer Res., December 15, 2003; 63(24): 8614 - 8622.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. A. Borgono, L. Grass, A. Soosaipillai, G. M. Yousef, C. D. Petraki, D. H. C. Howarth, S. Fracchioli, D. Katsaros, and E. P. Diamandis
Human Kallikrein 14: A New Potential Biomarker for Ovarian and Breast Cancer
Cancer Res., December 15, 2003; 63(24): 9032 - 9041.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. R. Kozak, M. W. Amneus, S. M. Pusey, F. Su, M. N. Luong, S. A. Luong, S. T. Reddy, and R. Farias-Eisner
Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis
PNAS, October 14, 2003; 100(21): 12343 - 12348.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.